ADC Therapeutics SA
For the period ended Dec 31, 2023. Filed Mar 13, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 13, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 2. Properties
We do not own any real property. The table below sets forth the sizes and uses of our leased facilities as of the date of this Annual Report:
| Location | Primary Function | Approximate Size |
|---|---|---|
| BiopôleRoute de la Corniche 3B 1066 Epalinges Switzerland | Head office | 292 m2 |
| 430 Mountain Avenue, 4th Floor Murray Hill, New Jersey 07974 United States | Clinical, commercial and U.S. operations | 965 m2 |
| 84 Wood LaneLondon, W12 0BZUnited Kingdom | Research and preclinical development | 2,200 m2 |
| 1510 Fashion Island Boulevard, Suite 205 San Mateo, California 94404 United States(1) | Chemistry manufacturing and control | 375 m2 |
(1)We do not intend to renew our lease at this location when it expires in June 2024. Thereafter, we intend for our CMC operations to be located in our New Jersey location.
We are not aware of any environmental issues or other constraints that would materially impact the intended use of our facilities.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.